Table 1.
Differences in OS and PFS according to the completeness of adjuvant TMZ treatment
| Variable | Total patients (n=750) |
Methylated (n=89) |
Unmethylated (n=128) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OS | PFS | OS | PFS | OS | PFS | |||||
| p-value | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | ||||
| TMZ < 3 cycles | n=93 | n=9 | n=17 | |||||||
| Median (mo) | 10.2±1.0 | 5.3±0.2 | 10.1+5.5 | 4.6±1.1 | 9.5±1.1 | 5.4±0.9 | ||||
| 95% Cl (mo) | 8.3-12.1 | 4.9-5.7 | 0-20.9 | 2.5-6.7 | 7.3-11.7 | 3.6-72 | ||||
| TMZ ≥ 3 cycles | n=160 | n=20 | n=30 | |||||||
| Median (mo) | 13.9±0.6 | 6.7±0.2 | 16.1±0.9 | 8.0±1.9 | 14.2±0.7 | 62±1.0 | ||||
| 95% Cl (mo) | 12.8-15.0 | 62-7.2 | 14.3-17.9 | 4.3-11.7 | 12.9-15.5 | 4.2-82 | ||||
| Patients who completed 6 cycles of adjuvant TMZ | n=407 | n=55 | n=67 | |||||||
| Median (mo) | 25.7±1.1 | 14.7±0.7 | 29.6±2.9 | 19.2±3.2 | 22.2±3.2 | 12.1±0.8 | ||||
| 95% Cl (mo) | 23.6-27.8 | 13.3-16.1 | 23.9-35.3 | 13.0-25.4 | 16.0-28.4 | 10.6-13.6 | ||||
| Patients who did not receive adjuvant TMZ | n=90 | n=5 | n=14 | |||||||
| Median (mo) | 6.5±0.9 | 3.8±0.2 | 5.8±0.9 | 4.2 | 4.9±2.2 | 3.8±0.4 | ||||
| 95% Cl (mo) | 4.6-8.4 | 3.4-4.2 | 4.1-7.5 | - | 0.7-9.1 | 3.0-4.6 | ||||
Kaplan-Meier and log rank tests. OS, overall survival; PFS, progression-free survival; TMZ, temozolomide; CI, confidence interval.